Xenon Pharmaceuticals(XENE)

BC - Burnaby

Pharmaceutical

Website LinkedIn Careers Page

Focus: Small Molecules for rare genetic diseases

Xenon Pharmaceuticals is a life sciences company focused on Small Molecules for rare genetic diseases.

Rare DiseasesNeurology

Funding Stage

PUBLIC

Open Jobs

15

Pipeline & Clinical Trials

XPF-001

Healthy Human Volunteers

Phase 1

Clinical Trials (1)

NCT00813670Single and Multiple Ascending Dose Safety Study of XPF-001 in Healthy Volunteers

Phase 1

14C-XEN1101

Healthy Volunteers

Phase 1

Clinical Trials (1)

NCT04952467Single-dose Mass Balance Recovery and Metabolite Profile and Identification of 14C-XEN1101

Phase 1

XPF-008

Healthy Volunteers

Phase 1

Clinical Trials (1)

NCT03340220Safety, Tolerability, and Pharmacokinetics (PK) of Single and Multiple Ascending Oral Doses of XEN1101.

Phase 1

XPF-008

Healthy Male Volunteers

Phase 1

Clinical Trials (1)

NCT03468725Safety, Tolerability, Pharmacokinetics and Effects on Transcranial Magnetic Stimulation of Oral Doses of XEN1101

Phase 1

XEN901

Healthy Volunteers

Phase 1

Clinical Trials (1)

NCT03467100Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of XEN901

Phase 1

XPF-005

Phase 1/2

Clinical Trials (1)

NCT02656043A Safety, Tolerability, Efficacy and Exposure Study of XEN801 Topical Gel

Phase 1/2

XPF-002

Primary Erythromelalgia

Phase 1/2

Clinical Trials (1)

NCT01486446Phase 2a, Exploratory Study to Evaluate the Safety, Efficacy, Tolerability and Pharmacokinetics of XPF-002 in Patients With Primary/Inherited Erythromelalgia

Phase 1/2

XPF-001

Primary Erythromelalgia

Phase 1/2

Clinical Trials (1)

NCT01090622Study of XPF-001 in the Treatment of Pain From Primary/Inherited Erythromelalgia (IEM)

Phase 1/2

XPF-002

Postherpetic Neuralgia

Phase 2

Clinical Trials (1)

NCT01195636A Crossover Study to Evaluate the Safety, Tolerability and Efficacy of XPF-002 in Subjects With Postherpetic Neuralgia (PHN)

Phase 2

XEN1101 10 mg

Major Depressive Disorder

Phase 2

Clinical Trials (1)

NCT05376150A Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 in Major Depressive Disorder

Phase 2

XPF-001

Phase 2

Clinical Trials (1)

NCT00954356Safety and Efficacy Study of XPF-001 to Treat Pain Following Wisdom Tooth Extraction

Phase 2

XEN1101

Phase 2

Clinical Trials (1)

NCT03796962A Study to Evaluate XEN1101 as Adjunctive Therapy in Focal Epilepsy

Phase 2

Azetukalner

Major Depressive Disorder

Phase 3

Clinical Trials (1)

NCT07076407A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)

Phase 3

Azetukalner

Bipolar Disorder

Phase 3

Clinical Trials (1)

NCT07172516A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)

Phase 3

XEN496

Phase 3

Clinical Trials (1)

NCT04639310XEN496 (Ezogabine) in Children With KCNQ2 Developmental and Epileptic Encephalopathy

Phase 3

XEN1101

Focal Onset Seizures

Phase 3

Clinical Trials (1)

NCT05614063A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures

Phase 3

Azetukalner

Major Depressive Disorder

Phase 3

Clinical Trials (1)

NCT06922110An Open-Label Study of Azetukalner in Major Depressive Disorder

Phase 3

XEN496

Phase 3

Clinical Trials (1)

NCT04912856An Open-Label Extension of the Study XEN496 (Ezogabine) in Children With KCNQ2-DEE

Phase 3

Azetukalner

Bipolar Depression

Phase 3

Clinical Trials (1)

NCT07217860An Open-label Study of Azetukalner in Bipolar I or II Depression (X-CEED-OLE)

Phase 3

XEN1101

Phase 3

Clinical Trials (1)

NCT05718817An Open-label Study of XEN1101 in Epilepsy

Phase 3

XEN1101

Primary Generalized Tonic-Clonic Seizures

Phase 3

Clinical Trials (1)

NCT05667142A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures

Phase 3

XEN1101

Focal Onset Seizures

Phase 3

Clinical Trials (1)

NCT05716100A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)

Phase 3

Azetukalner

Major Depressive Disorder

Phase 3

Clinical Trials (1)

NCT06775379A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder

Phase 3

Open Jobs (15)

Director, Distribution & Services

Senior Medical Science Liaison (NYC Tri-State)

Clinical Development

$208K - $234K/yr

Associate Director, Scientific Publications

Clinical Development

$170K - $215K/yr

Director, Regulatory Affairs, CMC

Clinical Development

Senior Medical Director, Clinical Development Psychiatry (BPD)

Clinical Development

$344K - $380K/yr

Medical Director/Senior Medical Director, Drug Safety and Pharmacovigilance, Medical Safety

Clinical Development

$285K - $369K/yr

Senior Medical Science Liaison (Northeast Region)

Clinical Development

$208K - $234K/yr

Senior Director, Supply Chain, Logistics

Research & Development

Vice President, Regulatory Affairs (Advertising, Promotion, and Labeling)

Clinical Development

Associate Director, Quality Assurance, GMP

Research & Development

$141K - $178K/yr

Associate Director, Quality Assurance, GMP

Research & Development

Director, Regulatory Affairs, CMC

Clinical Development

$193K - $220K/yr

Principal Scientist/Sr. Principal Scientist, CMC, Analytical Chemistry

Research & Development

$151K - $212K/yr

Associate Director/Director, Quality Assurance, GCP

Research & Development

$169K - $235K/yr

Associate Director, Scientific Communications

Clinical Development

$170K - $215K/yr

Interview Prep Quick Facts

Portfolio: 23 clinical trials

Top TAs: Neurology

SEC Filings: 2 available

Open Roles: 15 active jobs

Therapeutic Area Focus

9 pipeline

Marketed

Pipeline

Financials (FY2025)

Revenue

$0100%

R&D Spend

$168M58%

Net Income

-$182M

Cash

$143M

Source: SEC 10-K Filing

Hiring Trend

Stable

15

Open Roles

+2

Added

-0

Filled/Removed

Based on last 4 crawl cycles